Compare BridgeBio Pharma Inc (BBIO) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while YieldMax TSLA Option Income Strategy ETF trades at $21.84. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | TSLY | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.17 | $48.25 |
52-Week Low | $47.29 | $20.49 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
TSLY trades at $21.55, up 1.03% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF maintains a high dividend yield strategy, with recent weekly distributions averaging around $0.28 per share. Support and resistance levels are tightly clustered near the current price, indicating limited near-term price movement potential.
The outlook for TSLY is cautious due to capped upside from its option income structure and dependence on Tesla's volatility. Risks include missed participation in Tesla rallies and high distribution volatility. Analyst sentiment has shifted to neutral, reflecting concerns over sustainable yield and growth constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
